Anxiety studies

Virtual Reality Education Module in Reducing Anxiety and Increasing Knowledge in people with Prostate Cancer Undergoing Radiation Therapy

This study ended early.

Countries

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Virtual Reality to Reduce Anxiety, Agitation and Delirium in Critically Ill Patients

This study has finished and is no longer accepting participants.

Countries

United States

Sponsor

Milton S. Hershey Medical Center

High-intensity interval training counteracts the adverse effects of a short-term low-carbohydrate diet on anxiety but is less effective than moderate-intensity continuous training

This study isn't currently recruiting.

Countries

China

Sponsor

University of Macau

A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiet...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom

Sponsor

Janssen-Cilag International N.V.

A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in pat...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Italy

Sponsor

ABIOGEN PHARMA

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Denmark, Germany

Sponsor

GlaxoSmithKline Research & Development Limited

An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Ireland, Italy, + 2 others

Sponsor

Pfizer Ltd.

An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredut...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Belgium, Finland, Italy, + 1 other

Sponsor

sanofi-aventis recherche et développement

An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Czechia, Denmark, Finland, + 4 others

Sponsor

AstraZeneca AB

D-cycloserine augmented exposure therapy in patients with agoraphobia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

Charité Universitätsmedizin Berlin

Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Czechia, Finland, Germany, + 3 others

Sponsor

Institut de Recherches Internationales Servier

International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d...

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

elbion AG